Search Results

By Matthew Stenger  / Tuesday, January 6, 2015 12:00 PM

Somatic Tumor Neoepitopes as Basis for Response to CTLA-4 Inhibition in Melanoma

The molecular determinants of benefit from immune checkpoint inhibitor treatment have not been characterized. In a study reported in The New England Journal of Medicine, Snyder et al found that benefit of the anti–cytotoxic T-lymphocyte antigen 4 (CTLA-4) antibodies ipilimumab (Yervoy) and...